TFA
CRSP icon

Transamerica Financial Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Transamerica Financial Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$109 Sell
2
-2
-50% -$105 ﹤0.01% 1985
2026
Q1 		$190 Buy
4
+1
+33% +$53 ﹤0.01% 1642
2025
Q4 		$157 Buy
3
+2
+200% +$120 ﹤0.01% 1580
2025
Q3 		$65 Buy
+1
New +$57 ﹤0.01% 1557

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Transamerica Financial Advisors's CRSP Position: Q2 2026 in Review

Transamerica Financial Advisors reduced its CRISPR Therapeutics (CRSP) stake by 50% in Q2 2026, selling an estimated $105 and leaving 2 shares worth $109. The position accounts for ﹤0.01% of the portfolio, ranked #1985.

Transamerica Financial Advisors first reported a position in CRSP in Q3 2025 and has held it in 4 quarters since. The position peaked at $190 in Q1 2026. 522 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Transamerica Financial Advisors held 2 shares of CRISPR Therapeutics worth $109 as of Q2 2026.
  • Transamerica Financial Advisors sold 2 CRISPR Therapeutics shares in Q2 2026, an estimated $105.
  • CRISPR Therapeutics made up ﹤0.01% of Transamerica Financial Advisors's portfolio in Q2 2026, its #1985 holding.
  • Transamerica Financial Advisors first reported a position in CRISPR Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Transamerica Financial Advisors's CRISPR Therapeutics position peaked at $190 in Q1 2026.
  • 522 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Transamerica Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.